Pusch, Stefan 1979-
Stefan Pusch
Pusch, Stefan René, 1979-
VIAF ID: 81263765 (Personal)
Permalink: http://viaf.org/viaf/81263765
Preferred Forms
- 100 1 _ ‡a Pusch, Stefan René, ‡d 1979-
- 100 1 _ ‡a Pusch, Stefan ‡d 1979-
- 100 0 _ ‡a Stefan Pusch
4xx's: Alternate Name Forms (4)
5xx's: Related Names (6)
- 510 2 _ ‡a Deutsches Krebsforschungszentrum
- 510 2 _ ‡a Deutsches Krebsforschungszentrum ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 551 _ _ ‡a Karlsruhe ‡4 ortg ‡4 https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 510 2 _ ‡a Köln, Universiẗat
- 510 2 _ ‡a Universitätsklinikum Heidelberg ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Universitätsklinikum Heidelberg
Works
Title | Sources |
---|---|
Analysis of the subcellular localization, function, and proteolytic control of the Arabidopsis cyclin-dependent kinase inhibitor ICK1/KRP1. | |
The Arabidopsis thaliana F-box protein FBL17 is essential for progression through the second mitosis during pollen development | |
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody | |
Brain tumour cells interconnect to a functional and resistant network. | |
A cell-based MAPK reporter assay reveals synergistic MAPK pathway activity suppression by MAPK inhibitor combination in BRAF-driven pediatric low-grade glioma cells | |
Characterization of the epithelial membrane protein 3 interaction network reveals a potential functional link to mitogenic signal transduction regulation | |
Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma | |
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas | |
CIC protein instability contributes to tumorigenesis in glioblastoma | |
Control of cell proliferation, organ growth, and DNA damage response operate independently of dephosphorylation of the Arabidopsis Cdk1 homolog CDKA;1. | |
D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma | |
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma | |
A general G1/S-phase cell-cycle control module in the flowering plant Arabidopsis thaliana | |
Glioma IDH1 mutation patterns off the beaten track. | |
Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma. | |
Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma | |
Identification of kinase substrates by bimolecular complementation assays. | |
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity | |
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases | |
Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG. | |
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective | |
Interaktionsanalyse von CDKA;1 und anderen Zellzyklusregulatoren aus Arabidopsis thaliana | |
Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. | |
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy | |
Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E | |
Mutant IDH1 inhibits PI3K/Akt signaling in human glioma. | |
Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations. | |
NDRG1 prognosticates the natural course of disease in WHO grade II glioma. | |
NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis | |
OS10.2 R-2-Hydroxyglutarate shapes the immune microenvironment in IDH1-mutant gliomas. | |
OS2.2 Paracrine impairment of antitumor T cell immunity by IDH1-mutant gliomas. | |
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. | |
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. | |
Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p | |
Proximity ligation assay evaluates IDH1R132H presentation in gliomas | |
Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. | |
RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas | |
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations | |
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate | |
Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway | |
T-loop phosphorylation of Arabidopsis CDKA;1 is required for its function and can be partially substituted by an aspartate residue. | |
A vaccine targeting mutant IDH1 induces antitumour immunity. |